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Background: Smokers have a lower body weight compared to non-smokers. Smoking cessation is associated
with weight gain in most cases. A hormonal mechanism of action might be implicated in weight variations related
to smoking, and leptin might be implicated. We made secondary analyses of an RCT, with a hypothesis-free
exploratory approach to study the dynamic of leptin following smoking cessation.
Methods: We measured serum leptin levels among 271 sedentary smokers willing to quit who participated in a
randomized controlled trial assessing a 9-week moderate-intensity physical activity intervention as an aid for
smoking cessation. We adjusted leptin for body fat levels. We performed linear regressions to test for an association
between leptin levels and the study group over time.
Results: One year after smoking cessation, the mean serum leptin change was +3.23 mg/l (SD 4.89) in the control
group and +1.25 mg/l (SD 4.86) in the intervention group (p of the difference < 0.05). When adjusted for body fat
levels, leptin was higher in the control group than in the intervention group (p of the difference < 0.01). The mean
weight gain was +2.91 (SD 6.66) Kg in the intervention and +3.33 (SD 4.47) Kg in the control groups, respectively
(p not significant).
Conclusions: Serum leptin levels significantly increased after smoking cessation, in spite of substantial weight gain.
The leptin dynamic might be different in chronic tobacco users who quit smoking, and physical activity might
impact the dynamic of leptin in such a situation.
Clinical trial registration number: NCT00521391
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Tobacco use is the world leading cause of preventable
death [1]. For many smokers, smoking is viewed as a
means for weight control [2-5]. Smoking cessation is in-
deed associated with around 2.6 Kg of mean weight gain
after five years of quitting in men and 3.6 Kg in women
[6]. Efficient treatments or preventive interventions to
avoid weight gain following smoking cessation are lacking* Correspondence: semira.gonseth@gmail.com
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unless otherwise stated.[7]. Nevertheless, there is some promising evidence to-
wards physical activity (PA) being a solution. For instance,
a Cochrane review found that one year of regular PA fol-
lowing smoking cessation might help to decrease weight
gain [8].
Numerous studies argued that a hormonal mechanism
of action might be implicated in post-cessation weight
gain, and that leptin may be involved [9-12]. Leptin is a
cytokine, which is released from the adipose tissue and
acts centrally to suppress food intake and increase the
metabolic rate [13]. Leptin decreases the appetite after
eating: leptin rises with food intake and modifies the
balance between appetite stimulation and inhibition
in the hypothalamus, through an action involvingl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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food intake [14-16].
Leptin is considered as a potential mediator of weight
gain following smoking cessation [10,17,18] or as a cause
of differences in body weight observed between smokers
and nonsmokers [13]. “Crude” serum leptin levels are
lower in smokers in comparison with nonsmokers
[9,19-21], however this association disappears when lep-
tin is adjusted for body mass index (BMI) [22]. Only few
prospective studies, with small sample sizes and short
follow-up have explored the variations of leptin follow-
ing smoking cessation and their results are contradictory
[13,22-25].
Studies on the effect of physical activity on serum lep-
tin levels are scarce. According to a review, studies with
designs that manipulate energy balance showed that
serum leptin levels do not change with physical activity
unless a marked energy deficit occurs [26,27]. Published
studies about leptin variations and physical activity
assessed only intense physical activity, utilizing small
samples sizes and short times of intervention.
Given scarce information existing on the biodynamic
of leptin during smoking cessation and the plausibility of
leptin as a good candidate to explain weight gain follow-
ing smoking cessation, we attempted to describe the
biodynamics of serum leptin levels during smoking ces-
sation. We analyzed also if any variation in insulin secre-
tion and sensitivity impacted the leptin levels–as they
are both influenced by smoking cessation and physical
activity [28,29]. We performed secondary analyses of a
randomized controlled clinical trial (RCT) assessing
moderate physical activity as an aid for smoking cessa-
tion in sedentary subjects with an exploratory and
hypothesis-free approach.
Methods
We analyzed data from a population-based randomized
controlled trial assessing moderate PA as an aid for
smoking cessation. The main outcome of the RCT was
the one-year continuous smoking abstinence rate, which
was high but not statistically different between the inter-
vention group and the control group (27% versus 29%,
p = 0.71). These results are discussed in details elsewhere
[30]. Furthermore, the mean weight gain at one-year
follow-up was also not significantly different in the two
groups [31]. The full inclusion and exclusion criteria, as
well as the study design and procedure are described in
details elsewhere [30].
Smoking cessation program
The participants were randomly divided into two groups,
“intervention group” and “control group”. The sequence
of allocation of each group was remotely and randomly
generated by a computer, and concealment of allocationwas secured by means of sealed envelopes. All partici-
pants attended a 9-week program with a weekly 15-
minute individual-based smoking cessation intervention
combining counseling and prescription of nicotine re-
placement therapy (16-hour transdermal patches and/or
1- or 2-mg gum, 1-mg lozenge and 10-mg inhaler). This
program was based on international guidelines for smok-
ing cessation [32].
Subjects who did not stop smoking at the 5th week
after the inclusion visit, or who relapsed, were consid-
ered as smokers. Continuous abstinence was defined as
not smoking from week 5 until week 52 based on self-
report and validated by carbon monoxide measurements
(<10 ppm, see below).
Subjects enrolled in the intervention group attended a
9-week weekly 60-minute exercise intervention based on
a nationwide implemented moderate-intensity PA pro-
gram “ Allez Hop ! [‘Let’s go!’]” with PA-facilitators [33].
The group sessions were divided in three parts: discus-
sion on PA, 45-minute of moderate PA and debriefing.
The intervention was targeted to reach a score between
11 (« easy ») and 13 (« somewhat hard ») on the Borg
Rating of Percieved Exertion Scale [34]. Participants
were encouraged to practice 30-minute of moderate-
intensity PA four times per week.
Subjects enrolled in the control group attended a 9-
week weekly 60-minute health education program to en-
sure equal contact conditions. Control subjects partici-
pated to group sessions on healthy lifestyle, including
lectures, distribution of handouts and discussion about
diet, prevention of cardio-vascular disease and cancer,
and screening programs for breast and colon cancers.
We adaptated a validated program to the Swiss popula-
tion [35].
Serum fasting leptin, insulin and glucose levels were
assessed at baseline, and after 3, 6 and 12 months.
Data collection
Self-reported smoking abstinence was confirmed by car-
bon monoxide in exhaled air (<10 ppm), measured with
a Micro Smokerlyser® (Bedfont©). PA was quantified
with the self-administrated Physical Activity Frequency
Questionnaire (PAFQ) [36,37]. Volume of PA was then
calculated in METS*min/week for PA achieved in ≥4
METS, according to American Heart Association [38].
Participants wearing underwear were weighted to the
nearest 0.1 kg and their height was measured to the
nearest 0.5 cm. BMI was calculated using the formula:
weight [Kg]/ height2 [cm]. Proportion of lean and fat
masses were assessed by leg-to-arm bioelectrical imped-
ance analysis [39]. Plasma leptin was measured by radio-
immuno assay, using a kit from Linco Research Inc.
(St-Charles, M.O.), in serum samples removed in the
morning following an overnight fasting. For costs reasons,
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481 included participants. Percentage of body fat, BMI,
and leptin were analyzed as continuous variables. In
order to investigate leptin level while controlling for
change in adipose tissue, we defined the ratio leptin/
body fat levels as the ratio between leptin levels [mg/l]
and the percentage of body fat [%]. Differences of serum
leptin levels between men and women are well de-
scribed [40]. To estimate insulin secretion and insulin
sensitivity among participants, the Homeostasis model
assessment for insulin resistance (HOMA-IR) was cal-
culated according to the formula: fasting insulin [mU/l]
* fasting glucose [mmol/l]/22.5 [41]. Results are pre-
sented for all participants and stratified by sex.
Statistical analyses
We first performed a comparison between baseline char-
acteristics in the intervention and control group, using
two sample t-test for normal distributed variables, non
parametric Wilcoxon test for skewed variables and z-test
for binary variables. Follow-up time, abstinence duration,
total physical activity and proportion of continuous ab-
stinent at 12 months were compared in the two groups
using Wilcoxon and z-test. Twelve months changes
in weight, BMI, body fat, HOMA-IR, leptin and ratio
leptin/body fat (ratio leptin/body fat) were compared
using two-sample t-tests.
Changes in leptin variables between the baseline and the
subsequent visits were estimated by performing simple
linear regressions by study group and by smoking status.
We also performed a multivariate linear regression to esti-
mate the impact of potential confounding variables to the
association between leptin levels and study group. Individ-
uals with missing data were excluded from these analyses.
We used a polynomial longitudinal model in order to
compare the dynamics across the time of the ratio leptin/
body fat in the two groups of randomization (the methods
are described in the Additional file 1).
We used the R system for all statistical computations
and graphics (v 2.11.1, http://www.r-project.org/, func-
tion “lme”, library “nlme”).
Results
The study population included 271 participants, 136 in
the control group and 135 in the intervention group. No
statistically significant difference was observed in base-
line characteristics between the control and intervention
groups (Table 1). The follow-up had a median duration
of 55 (IQ = 11-59) weeks and was similar between the
intervention and control groups. Of the 271 participants,
81 (29.9%) were continuous abstinent (CO-verified) for
the entire duration of the study. During follow-up,
participants showed a median duration of abstinence
of 11.9 (IQ = 4-52.3) weeks. In the control group, themedian abstinence was 16.5 (IQ = 4.5–51.7) weeks, while
in the intervention group it was 11.4 (IQ = 3.5 – 53.5)
weeks (p of the difference = 0.95). After 12 months of
follow-up, the abstinence rate was 50.96% in the control
group, and 50.76% in the intervention group (p of the
difference = 0.97). The total physical activity in ≥4 METS
after 12 months was 879 (203–2240) METS*min/week
in the control group, and it was 1642 (758–3084)
METS*min/week in the intervention group (p of the
difference = 0.01).
Table 2 shows the changes of metabolism-related vari-
ables at 3, 6 and 12 months after the baseline visit by
study group. The change of leptin was almost signifi-
cantly higher in the control group at 6 months (p =
0.08), and significantly higher at 12 months (p = 0.014).
The change of the ratio leptin/body fat was higher in the
control group at each visit, and it was strongly signifi-
cant at 6 and 12 months of follow-up (p = 0.024, 0.001
and 0.008, at 3, 6 and 12 months, respectively), as illus-
trated in the Figure 1. The other variables did not show
any significant change between the groups. Table 3
shows the same variables by smoking status, independ-
ently of the study groups. No significant association was
observed.
In the multivariate linear regression, the change of the
ratio leptin/body fat was significantly different according
to the study group, being lower in the intervention
group at each visit (Table 4). Fasting insulin and glucose
levels did not impact this association (no significant p
values, expected for insulin at 6 months, where p =
0.011) neither did the smoking status.
Applying a longitudinal model, we found that the
mean ratio leptin/body fat increased in the first 35 weeks,
and decreased thereafter, following a quadratic curve
(p < 0.001 for both the linear and quadratic term, Additional
file 2: Figure S1). We also found a significant interaction
between the study group and time (p = 0.04), attesting a
different pattern of ratio leptin/body fat over the follow up
for the control and the intervention group. Namely, the
intervention group showed an attenuated dynamics of the
ratio leptin/body fat across the time, with a maximum
gain of 0.04 ml/l instead of 0.07 ml/l at 35 weeks, and a
final gain of 0.02 ml/l instead of 0.04 ml/l at the median
follow-up duration of 55 weeks.
Finally, with a piecewise longitudinal model applied to
the 234 participants who stopped smoking at least once,
we could give a separate estimate of the ratio leptin/
body fat change during abstinence and relapse episodes
during follow-up (Additional file 2: Figure S2). Physical
activity still had an influence on leptin dynamics during
abstinence periods, with a more important increase for
the control than the intervention group (p = 0.03). The
model also showed a significant effect of sex on ratio
leptin/body fat initial levels and dynamics across time:
Table 1 Baseline characteristics by study group
Control (n = 136) Intervention (n = 135) p
Men, No (%) 81 (59.6) 77 (57.0) 0.674
Age [years], mean (SD) 42.7 (9.3) 41.7 (9.7) 0.419
Number of cig./d, median (IQR) 25 (20–30)† 25 (20–30) 0.697
No of years of education, mean (SD) 12.6 (1.8)‡ 12.5 (1.8) 0.782
Physical activity in >4 METS, median (IQR) 936 (188–2047)* 866 (190–2403)** 0.942
Weight [Kg], mean (SD) 70.7 (12.9) 71.8 (15.9) 0.526
BMI, mean (SD) 23.8 (3.23) 24.1 (4.12) 0.526
Percent of body fat, mean (SD) 25.6 (5.7) 25.8 (7.0) 0.876
HOMA-IR 2.22 (1.13) 2.45 (1.39) 0.17
Leptin [mg/l], median (IQR) 6.4 (4.2 - 11.7) 7.2 (4.3 - 12.2) 0.376
Ratio leptin/body fat [mg/l], median (IQR) 0.26 (0.17 - 0.43) 0.28 (0.19 - 0.48) 0.290
† n = 135 ; ‡ n = 133 ; *n = 115 ; **n = 111
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cantly larger than men (0.48 ml/l vs. 0.20 ml/l, p <
0.001), and a more important dynamics over the follow-
up. Relapse to smoking modified the quadratic pattern
of the adjusted leptin, leading to an abrupt linear de-
crease of the mean adjusted leptin when the relapse epi-
sode started (p < 0.001).
Discussion
We found that the levels of leptin significantly increased
during the study period in all study participants, inde-
pendently of their study group. The increase of serum
leptin was the greatest (+5.27 mg/l, SD 5.59) in continu-
ous abstinent participants from the control group, which
constitutes an increase of more than 82% compared with
the mean control group’s baseline leptin levels. The
levels of adjusted for body fat leptin increased after
12 months in the control group, but not in the interven-
tion. In addition, the participants in both groups gained
substantial weight (e.g., between +6.04 Kg (SD 3.87) inTable 2 Change in follow-up variables at 3, 6, and 12 months
group
3 months
Intervention Control p¶ Interven
Body weight [Kg] 2.31 (2.72) 2.15 (2.48) 0.665 2.84 (5
BMI [kg/m2] 0.8 (0.91) 0.73 (0.89) 0.57 1.01 (1
Body fat [%] 1.76 (4.43) 1.09 (2.13) 0.269 2.53 (5
HOMA-IR 0.1 (1.16) 0.04 (1.22) 0.735 0.33 (1
Fasting leptin [ug/l] 1.78 (3.79) 2.37 (3.61) 0.273 1.73 (5
Ratio leptin/body fat 0 (0.19) 0.06 (0.1) 0.024* −0.04 (0
BMI: Body Mass Index; HOMA-IR: homeostasis model assessment for insulin resistan
¶ p-value, assessed by univariate linear regression analysis.
Values are expressed in means (standard deviation).
* p <0.05;**p <0.01.control abstinent group and +4.66 Kg (SD 4.18) in inter-
vention abstinent group over 12 months). Our findings
bring more solid evidence of the post-cessation leptin
dynamic than what was previously found in smaller
studies with shorter follow-up on that same subject
[13,22-25].
It is probable that leptin levels increased after smoking
cessation because the study’s participants increased their
food intake. Indeed, an increase in food intake has been
widely observed during smoking cessation [42]. It is
caused, most probably, by a compensatory eating behav-
ior in response to the tobacco withdrawal [43]. Accord-
ing to previous studies in nonsmokers, leptin increases
with an increase in food intake. For instance, in a study
conducted by Weigle et al., overeating rapidly increased
serum leptin levels by about 40 percent [44]. Moreover,
the observed increase of leptin was independent of any
major influence of insulin secretion or sensitivity.
However, when strictly considering the leptin pathway,
our findings were counter-intuitive. Indeed, the expectedafter the baseline visit among all participants, by study
6 months 12 months
tion Control p Intervention Control p
.99) 3.02 (3.51) 0.822 2.91 (6.66) 3.33 (4.47) 0.633
.83) 1.03 (1.21) 0.928 1 (1.98) 1.14 (1.53) 0.624
.75) 1.86 (3.19) 0.477 2.49 (5.24) 2.53 (2.95) 0.957
.08) 0.24 (1.03) 0.596 0.67 (1.56) 0.78 (1.92) 0.731
.77) 3.2 (4.42) 0.08 1.25 (4.86) 3.23 (4.89) 0.014*
.23) 0.08 (0.12) 0.001** −0.02 (0.22) 0.07 (0.12) 0.008**
ce.
Figure 1 Ratio leptin/body fat, by study group over the study period (at baseline visit, and at 3, 6 and 12 months).
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secutive decrease in the appetite, thus in food intake. No
weight gain should thus arise in such a situation [45],
unlike what we observed in our study. Several hypoth-
eses can be made to explain this apparent contradiction.
For instance, the participants might have been present-
ing a resistance to leptin, i.e. a rise in leptin was not pro-
ducing a decrease in appetite (and thus in food intake
and body weight) as expected. Chronic tobacco use
might induce such a leptin resistance, in a similar way
that it is known to produce an insulin resistance, as de-
scribed by Willi et al. [46]. At this stage, the mechanisms
of action of such a metabolic effect of smoking on leptin
could only be hypothesized. For instance, a chronicTable 3 Change in follow-up variables at 3, 6, and 12 months a
status (continuous abstinence vs. relapse)
3 months
Smoking Abstinence p Smok
Body weight [Kg] 2.25 (2.35) 1.99 (2.83) 0.584 3.05 (
BMI [kg/m2] 0.78 (0.89) 0.68 (0.95) 0.539 1.08 (1
Body fat [%] 1.49 (3.19) 1.23 (4) 0.784 2.18 (3
HOMA-IR 0.1 (1.56) 0.03 (1.03) 0.763 0.27 (1
Fasting leptin [ug/l] 1.8 (4.3) 2.03 (3.67) 0.734 1.88 (6
Ratio leptin/body fat 0 (0.15) 0.03 (0.17) 0.513 −0.02 (0
Values are expressed in means (standard deviation).inflammation induced by smoking metabolites could
damage the leptin receptors. Other reasons for these ap-
parent contradictory results might involve other hor-
mones or pathways, like insulin for instance. Moreover,
it is possible that the increased eating behavior due to
the tobacco withdrawal is so strong that is not influ-
enced by the action of leptin. Further research on this
subject is needed.
In addition, moderate physical activity seemed to at-
tenuate the increase in serum leptin levels after smoking
cessation. Indeed, we found that the participants in the
intervention group, who underwent a 9-week smoking
cessation program, consisting of 60 minutes per week of
moderate physical activity, had a lower increase in serumfter the baseline visit among all participants, by smoking
6 months 12 months
ing Abstinence p Smoking Abstinence p
4) 2.45 (6.15) 0.599 2.45 (3.64) 3.2 (7.42) 0.520
.44) 0.86 (1.87) 0.535 0.84 (1.2) 1.1 (2.29) 0.468
.1) 2.09 (6.01) 0.955 2.5 (2.84) 2.57 (5.47) 0.948
.2) 0.27 (0.93) 0.977 0.99 (2.32) 0.83 (1.54) 0.681
.82) 2.63 (4.59) 0.505 1.83 (4.14) 2.56 (5.44) 0.455
.18) 0.02 (0.22) 0.529 0 (0.11) 0.03 (0.24) 0.564
Table 4 Multivariate linear regression analysis of the changes in the ratio leptin/body fat at 3, 6 and 12 months after
the baseline visit, respectively
3 months (n = 124) 6 months (n = 95) 12 months (n = 101)
RC p RC p RC p
Intercept −0.084 0.469 −0.072 0.609 0.145 0.579
Intervention −0.238 0.040* −0.426 0.002** −0.115 0.030*
Smoking status −0.062 0.602 −0.122 0.417 −0.018 0.749
Fasting insulin [mU/l] 0.204 0.084 0.466 0.008** 0.005 0.174
Fasting glucose [mmol/l] 0.091 0.429 −0.057 0.705 −0.023 0.655
RC : regression coefficient.
* p <0.05;**p <0.01.
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group. It is interesting to note that we did not see, as
theoretically expected, an increase in weight gain in the
intervention group compared to the control group, des-
pite the fact that the intervention group had lower
serum leptin levels. Here again, the underlying mecha-
nisms of action of such an effect remain unknown and
can only be hypothesized at this stage. In accordance
with our first interpretation, what we might see here
could be a beneficial impact of physical activity on the
leptin resistance -if existing- and induced by smoking,
i.e. physical activity might reduce this leptin resistance.
We have already known that physical activity had several
beneficial impacts on type 2 diabetes insulin resistance
[47], and it could produce a similar action on leptin.
Such potential beneficial action of physical activity on
leptin resistance, if confirmed, might occur, for instance,
through a change in the balance between muscular and
fat masses, in favor of muscle.
According to our model, we found that smoking cessa-
tion triggered an increase in serum leptin levels in both
groups, but physical activity attenuated this increase,
leading to substantially recover the initial leptin levels at
the end of follow-up. This could be interpreted as a de-
crease in leptin resistance over time after smoking cessa-
tion, similar to a “healing process”. This might also
reflect that the eating behavior due to the tobacco with-
drawal attenuates over time. Incidentally, our model
showed that a smoking relapse triggered an abrupt de-
crease in leptin levels. This fall in leptin could be con-
secutive to the effect that, when a relapse occurred,
smoking acted as a substitute for food, then food intake
decreased followed by a decrease in serum leptin levels.
Several limitations of our study have to be mentioned.
First, the physical activity program of our study was of
very moderate intensity, which probably underestimated
the potential effect of physical activity on metabolic
homeostasis and was discussed also elsewhere [30]. Sec-
ond, a vast majority of participants – both in the inter-
vention and in the control group – relapsed at different
stages during the study. The longitudinal models weused in the supplementary analyses allowed counteract-
ing this limitation, taking into account information for
each participant, independently of the beginning and the
duration of her or his smoking abstinence and relapse.Conclusions
We found that serum leptin levels significantly increased
after smoking cessation, while the study participants
gained substantial weight in the same time period. This
finding is in discordance with the theoretical effects of
leptin. Several hypotheses could explain these findings,
including for instance a leptin resistance in smokers.
These hypotheses need to be further investigated. We
also found that moderate physical activity might have at-
tenuated this potential leptin resistance. This study
brings additional arguments towards the hypothesis that
leptin would be implicated in weight gain after smoking
cessation.Additional files
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